SCHEMBL2814136

SCHEMBL2814136

CC(=O)OOc1ccc(Cc2nc(C(N)=O)c(NC(=O)Nc3ccc(C(C)C)cc3)[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
RAB9A P51151 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
SAE1 Q9UBE0 1/20 0.38
UBA2 Q9UBT2 1/20 0.38
MAPT P10636 2/20 0.37
PKM P14618 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
RET P07949 1/20 0.36
GHSR Q92847 1/20 0.36
LMNA P02545 1/20 0.35
COPS5 Q92905 1/20 0.35
PLG P00747 1/20 0.35
KLK1 P06870 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814139 0.91 KMT2A (0.44) KMT2AMEN1RAB9ACA12CA1
SCHEMBL2815380 0.89 MEN1 (0.57) KMT2AMEN1RAB9ACA12CA1
SCHEMBL2816333 0.85 RAB9A (0.43) KMT2AMEN1RAB9ACA12CA1
SCHEMBL2816165 0.84 COPS5 (0.43) KMT2AMEN1RAB9ACA12CA1
SCHEMBL2814969 0.83 FLT3 (0.43) KMT2AMEN1CA2SAE1UBA2
SCHEMBL13132948 0.83 MAPT (0.43) KMT2AMEN1RAB9ACA12CA1
SCHEMBL2814845 0.81 CA12 (0.43) KMT2AMEN1RAB9ACA12CA1
SCHEMBL17957262 0.80 MEN1 (0.58) KMT2AMEN1RAB9ACA12CA1
SCHEMBL2818220 0.80 SAE1 (0.42) KMT2AMEN1RAB9ACA12CA1
SCHEMBL2816764 0.80 MAPT (0.48) KMT2AMEN1MAPTSMN1; SMN2GRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US claimed
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249132-A1 IMIDAZOLE DERIVATIVES SDHA, SDHB, TPD52L2 KMT2A 1034/4885MEN1 171/4885RAB9A 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.